In phase I/Ib trials of patients with hematologic malignancies, MBG453 alone or in combination with Spartalizumab demonstrated anti-tumor efficacy [243].TSR-022 (Tesaro), a humanized anti-TIM-3 IgG4 ab with unreported Gal-9 neutralizing activity, has been administered as a monotherapy or in combination with anti-PD1, TSR-042 (Tesaro), in patients with melanoma or NSCLC [244,245]. This evidence concerns the gene LGALS9 and hematologic disorder.